State of Wisconsin Investment Board Has $211.06 Million Position in Pfizer, Inc. (PFE)
State of Wisconsin Investment Board increased its position in shares of Pfizer, Inc. (NYSE:PFE) by 4.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,283,435 shares of the biopharmaceutical company’s stock after buying an additional 289,030 shares during the period. Pfizer accounts for 0.7% of State of Wisconsin Investment Board’s holdings, making the stock its 24th biggest holding. State of Wisconsin Investment Board owned about 0.38% of Pfizer worth $211,061,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Shine Investment Advisory Services Inc. bought a new position in Pfizer during the second quarter worth $102,000. D. Scott Neal Inc. raised its stake in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer during the first quarter worth $121,000. Cascade Investment Advisors Inc. raised its stake in Pfizer by 89.1% during the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares during the last quarter. Finally, Perennial Advisors LLC raised its stake in Pfizer by 7.9% during the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 376 shares during the last quarter. 69.36% of the stock is owned by institutional investors and hedge funds.
Shares of Pfizer, Inc. (PFE) opened at $35.37 on Friday. The company has a market cap of $211,960.00, a PE ratio of 14.15, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer, Inc. has a 12-month low of $30.51 and a 12-month high of $36.78.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.61 earnings per share. equities analysts forecast that Pfizer, Inc. will post 2.6 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.62%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio is 78.53%.
A number of brokerages recently weighed in on PFE. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Berenberg Bank set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Tuesday, October 3rd. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target for the company. in a report on Wednesday, September 13th. Finally, Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $38.48.
In other news, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the sale, the insider now owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the sale, the insider now directly owns 132,124 shares in the company, valued at approximately $4,492,216. The disclosure for this sale can be found here. In the last ninety days, insiders sold 374,621 shares of company stock worth $12,796,098. Insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.